Prosecution Insights
Prosecution Insights
6 pending office actions • 2 art units • 5 examiners • 2 of 6 (33%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 2 | 65.4% | +23.5% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| BUTTICE, AUDREY L | 1 | 47.1% | +26.0% |
| MCCORMICK, CATHERINE LYNN | 1 | 48.8% | +35.6% |
| BATES, KEENAN ALEXANDER | 1 | 44.8% | +76.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835218 | METHODS OF REPEAT DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | CANDELARIA, JULIANA IRENE | — |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632026 | DUX4 EXPRESSING CELLS AND USES THEREOF | BATES, KEENAN ALEXANDER | 45d overdue |
| 17637789 | CD24 EXPRESSING CELLS AND USES THEREOF | MCCORMICK, CATHERINE LYNN | 63d |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — |
| 18561682 | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS | BUTTICE, AUDREY L | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835218 | METHODS OF REPEAT DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | CANDELARIA, JULIANA IRENE | — | §103§112 | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18561682 | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS | BUTTICE, AUDREY L | — | §103DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 17637789 | CD24 EXPRESSING CELLS AND USES THEREOF | MCCORMICK, CATHERINE LYNN | 1638 | §102 | Final Rejection | 63d | AI Ready | Feb 23, 2022 |
| 17632026 | DUX4 EXPRESSING CELLS AND USES THEREOF | BATES, KEENAN ALEXANDER | 1631 | §103Other | Final Rejection | 45d overdue | AI Ready | Feb 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial